Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Altoona Center for Clinical Research PC

Neither a doctor nor a teaching hospital

Research payments

$9,132,932

781 payments

Through program year 2025, Altoona Center for Clinical Research PC is reported as receiving $9,132,932 in research payments, across 781 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,086,863 152
2024 Research $1,775,574 65
2023 Research $1,603,321 72
2022 Research $1,103,880 84
2021 Research $1,103,498 122
2020 Research $692,879 158
2019 Research $766,917 128

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $4,217,427 124 payments
  2. Pfizer Inc. $2,857,105 184 payments
  3. Regeneron Pharmaceuticals, Inc. $768,940 119 payments
  4. Amgen Inc. $371,667 14 payments
  5. Horizon Therapeutics plc $198,443 9 payments
  6. Moderna TX, Inc. $143,955 36 payments
  7. GlaxoSmithKline, LLC. $113,023 64 payments
  8. Teva Pharmaceuticals USA, Inc. $106,238 30 payments
  9. Radius Health, Inc. $75,073 63 payments
  10. Dr.Reddy's Laboratories,Inc. $69,730 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $2,294,282 58 payments
  2. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $697,303 99 payments
  3. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $434,945 12 payments
  4. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $406,979 7 payments
  5. A Phase 3B, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity $361,519 1 payment
  6. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $355,434 4 payments
  7. A Study of Retatrutide (Ly3437943) in Participants Who Have Obesity Or Overweight (Triumph-1) $341,354 2 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity Or Overweight and Chronic Low Back Pain (Triumph-7) $245,665 1 payment
  9. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3016859 for the Treatment of Osteoarthritis $231,181 4 payments
  10. A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of Ly3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease $198,626 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record